The purpose of this Study is to Assess Safety and Pharmacokinetics of megavec 400 mg (Imatinib mesylate) under Fasted Conditions in Healthy Male Subjects.

• Inclusion Criteria:

  • Healthy and male subjects aged 20 to 55 years
  • The subject has a Body weight ≥55 kg and ideal body weight (IBW) within ±20%
  • A Subject who was judged to be healthy by the investigator to participate in this study based on screening results (according to standard reference index updated recently)
  • A subject who provided written informed consent to participate in this study and cooperative with regard to compliance with study related constraints.

• Exclusion Criteria:

  • A subject with sign or symptoms or previously diagnosed disease of respiratory, cardiovascular, endocrinology, liver, kidney, hematology, neurology and psychology function or other significant diseases and history
  • Known allergy or hypersensitivity to the study medication
  • AST or ALT greater than 1.25 times the upper limit of reference range or Total bilirubin greater than 1.25 times the upper limit of reference range base on screening results
  • A subject judged ineligible by the investigator to participate in this study for other reason containing clinical laboratory tests